Merck Nixes Prostate Cancer Study as Keytruda Therapy Disappoints

Merck & Co scrapped a late-stage trial of a combination therapy with its cancer drug Keytruda as interim data showed it was unlikely to meet the main goals.

Related Keywords

United States ,Bengaluru ,Karnataka ,India ,Bhanvi Satija ,Mara Goldstein ,Arun Koyyur ,Astellas Pharma Inc ,Pfizer Inc ,Merck Co On ,Reuters ,New Jersey Based ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Of The Prostate ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Biologic Therapy ,Iologics ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Prostatic ,Immunotherapy ,Lung ,Tumor ,